An illustration depicts cells in an Alzheimer’s-affected brain, with abnormal levels of beta amyloid protein clumping together to form plaques that collect between neurons and disrupt cell function.

Panelists discuss how amyloid-targeting therapies for Alzheimer disease represent a breakthrough drug class that works by binding to and removing beta-amyloid plaques through various mechanisms ...

For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from the brains of people destined to develop Alzheimer’s dementia can ...

Certain neurodegenerative disorders are characterized by the progressive accumulation of insoluble deposits of distinct misfolded proteins. In general, mutations causing inherited forms of the ...

Roche Holdings AG (OTC:RHHBY) on Thursday presented new data at the AD/PD 2025 International Conference on Alzheimer’s and ...

An experimental drug appears to reduce the risk of Alzheimer's-related dementia in people destined to develop the disease in their 30s, 40s or 50s, according to the results of a new study.

A recent study tests a new drug, gantenerumab on people with a genetically inherited form of Alzheimer’s disease. For people with this condition, dementia is almost inevitable. Gantenerumab ...

Labcorp's pTau-217/Beta Amyloid 42 Ratio blood test meets the performance criteria to confirm amyloid pathology consistent with Alzheimer's disease BURLINGTON, N.C., April 2, 2025 /PRNewswire ...

Roche has reported preliminary results on its Alzheimer’s disease prospect trontinemab. An early look at the phase 1b/2a data showed amyloid levels fell below a disease threshold in 81% of ...